



**ASX & MEDIA RELEASE
22 NOVEMBER, 2011**

MARSHALL EDWARDS TO HOST ANNUAL MEETING OF STOCKHOLDERS

Novogen Limited's subsidiary, Marshall Edwards, Inc., (NASDAQ: MSHL) has made the following announcement.

San Diego – 22 November, 2011 – Marshall Edwards, Inc. (Nasdaq: MSHL), an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, will host its Annual Meeting of Stockholders at 10:00 am Pacific time on Thursday, 1 December, 2011 at its offices, located at 11975 El Camino Real, Suite 101, San Diego, California, to consider and vote on certain matters, including the election of directors, the amendment and restatement of the company's equity compensation plan and the ratification of the appointment of the Company's independent registered public accounting firm. In addition, Daniel P Gold, PhD, President and Chief Executive Officer, will present a brief update on the company and its lead oncology drug candidates. A live webcast of the meeting will be accessible at www.marshalledwardsinc.com/investor.

About Marshall Edwards

Marshall Edwards, Inc. is a San Diego-based oncology company focused on the clinical development of novel anti-cancer therapeutics. The company's lead programs focus on two families of small molecules that result in the inhibition of tumour cell metabolism. The first and most advanced is a NADH oxidase inhibitor program that includes lead candidate ME-143. The company initiated a Phase I clinical trial of intravenous ME-143 in patients with solid refractory tumours in September 2011 and expects final data from the trial by the second quarter of 2012. The second program is a family of mitochondrial inhibitors that includes lead candidate ME-344. The company is currently conducting the necessary pre-clinical animal toxicity studies to support submission of an Investigational New Drug (IND) application for ME-344 in the first quarter of 2012. For more information, please visit www.marshalledwardsinc.com.

About Novogen Limited

Novogen Limited (ASX: NRT Nasdaq: NVGN) is an Australian biotechnology company based in Sydney, Australia. Novogen conducts research and development on oncology therapeutics through its subsidiary, Marshall Edwards, Inc., and is developing glucan technology through its subsidiary, Glycotex, Inc. More information on the Novogen group of companies can be found at www.novogen.com.

ISSUED FOR	:	NOVOGEN LIMITED
LISTINGS	:	ASX (CODE NRT), NASDAQ (CODE NVGN).
FOR FURTHER INFORMATION :	:	PETE DE SPAIN, SR DIRECTOR IR AND CORPORATE COMMUNICATIONS, MARSHALL EDWARDS, INC. TEL +1 858-792-3729 http://www.marshalledwardsinc.com
ISSUED BY CONTACT	:	WESTBROOK COMMUNICATIONS IAN WESTBROOK TEL (02) 9231 0922